Sieve analysis: methods for assessing from vaccine trial data how vaccine efficacy varies with genotypic and phenotypic pathogen variation.

A key component in the evaluation of efficacy of a vaccine to protect against disease caused by an antigenically diverse infectious pathogen in a preventative vaccine trial is assessing how vaccine-induced protection depends on genotypic and phenotypic variations of the exposing pathogen. This assessment is made by comparing pathogen isolates between infected vaccinated subjects and infected unvaccinated subjects. A survey of efficacy trial reports reveals a lack of systematic, quantitative investigation in this question. Analysis tools for testing if vaccine protection against disease is superior against some pathogen strains, and for estimating the magnitude of this differential vaccine protection, are described. The broad applicability of the methods is illustrated through analysis of isolates taken from persons infected while participating in vaccine trails for cholera, HIV-1, hepatitis B, rotavirus, and pneumococcus. These analyses reveal intriguing trends for Genentech's monovalent rgp120 HIV-1 vaccine, for two whole-killed-cell oral cholera vaccines, and for other vaccines.

[1]  G. Overturf,et al.  Infection caused by Streptococcus pneumoniae in children with sickle cell disease: epidemiology, immunologic mechanisms, prophylaxis, and vaccination. , 1992, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[2]  W H Mosley,et al.  Seroepidemiologic studies during a simultaneous epidemic of infection with El Tor Ogawa and classical Inaba Vibrio cholerae. , 1970, The Journal of infectious diseases.

[3]  S. Pyrhönen,et al.  Clinical trial of a subunit influenza vaccine. , 1981, Scandinavian journal of infectious diseases.

[4]  W. Li,et al.  Estimating evolutionary distances between DNA sequences. , 1996 .

[5]  A. Trkola,et al.  Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1 , 1996, Journal of virology.

[6]  P B Gilbert,et al.  Statistical methods for assessing differential vaccine protection against human immunodeficiency virus types. , 1998, Biometrics.

[7]  M E Halloran,et al.  Interpretation and estimation of vaccine efficacy under heterogeneity. , 1992, American journal of epidemiology.

[8]  T. Wrin,et al.  Genetic and immunologic characterization of viruses infecting MN-rgp120-vaccinated volunteers. , 1997, The Journal of infectious diseases.

[9]  S. Siegel,et al.  Nonparametric Statistics for the Behavioral Sciences , 2022, The SAGE Encyclopedia of Research Design.

[10]  A. Agresti.  Analysis of Ordinal Categorical Data , 1985 .

[11]  G. Dinant,et al.  The Efficacy of Influenza Vaccination in Elderly Individuals: A Randomized Double-blind Placebo-Controlled Trial , 1994 .

[12]  D. Sack,et al.  ABO blood groups and cholera: new observations on specificity of risk and modification of vaccine efficacy. , 1989, The Journal of infectious diseases.

[13]  P. McCullagh.  Regression Models for Ordinal Data , 1980 .

[14]  R. Black,et al.  Protection of Peruvian children against rotavirus diarrhea of specific serotypes by one, two, or three doses of the RIT 4237 attenuated bovine rotavirus vaccine. , 1989, The Journal of infectious diseases.

[15]  P G Smith,et al.  Assessment of the protective efficacy of vaccines against common diseases using case-control and cohort studies. , 1984, International journal of epidemiology.

[16]  A. Nisalak,et al.  Protection against Japanese encephalitis by inactivated vaccines. , 1988, The New England journal of medicine.

[17]  C. Broome,et al.  Pneumococcal Disease after Pneumococcal Vaccination , 1980 .

[18]  N. E. Breslow.  Statistical Methods in Cancer Research , 1986 .

[19]  David R. Cox.  The analysis of binary data , 1970 .

[20]  Yunus,et al.  Field trial of oral cholera vaccines in Bangladesh: results from three-year follow-up , 1990, The Lancet.

[21]  A. Trkola,et al.  Immunological and Virological Analyses of Persons Infected by Human Immunodeficiency Virus Type 1 while Participating in Trials of Recombinant gp120 Subunit Vaccines , 1998, Journal of Virology.

[22]  D. Sack,et al.  Field trial of inactivated oral cholera vaccines in Bangladesh: results from 5 years of follow-up. , 1996, Vaccine.

[23]  L. Dublin,et al.  Studies on Immunizing Substances in Pneumoeoeei. VIII. Report on Field Tests to determine the Prophylactic Value of a Pneumococeus Antigen. , 1938 .

[24]  J. Davide,et al.  Conserved sequence and structural elements in the HIV-1 principal neutralizing determinant. , 1990, Science.

[25]  Subhash R. Lele,et al.  Maximum likelihood estimation in semiparametric selection bias models with application to AIDS vaccine trials , 1999 .

[26]  R. Glass,et al.  Safety and Efficacy of High-dose Rhesus-Human Reassortant Rotavirus Vaccines-Report of the National Multicenter Trial , 1996, Pediatrics.

[27]  R. Gray.  A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk , 1988 .

[28]  M. Heidelberger,et al.  PREVENTION OF PNEUMOCOCCAL PNEUMONIA BY IMMUNIZATION WITH SPECIFIC CAPSULAR POLYSACCHARIDES , 1945, The Journal of experimental medicine.

[29]  M. Halloran,et al.  Exposure efficacy and change in contact rates in evaluating prophylactic HIV vaccines in the field. , 1994, Statistics in medicine.

[30]  T. Fleming,et al.  Intermediate-size trials for the evaluation of HIV vaccine candidates: a workshop summary. , 1997, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

[31]  P B Gilbert,et al.  Comparison of competing risks failure time methods and time-independent methods for assessing strain variations in vaccine protection. , 2000, Statistics in medicine.

[32]  A. Trkola,et al.  Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG , 1995, Journal of virology.

[33]  M Lunn,et al.  Applying Cox regression to competing risks. , 1995, Biometrics.

[34]  B. Plikaytis,et al.  Pneumococcal vaccine efficacy in selected populations in the United States. , 1986, Annals of internal medicine.

[35]  S. Chiba,et al.  Efficacy of rhesus rotavirus vaccine MMU-18006 against gastroenteritis due to serotype 1 rotavirus. , 1994, Vaccine.

[36]  M. Tanner,et al.  Randomised trial of efficacy of SPf66 vaccine against Plasmodium falciparum malaria in children in southern Tanzania , 1994, The Lancet.

[37]  Interpretability and robustness of sieve analysis models for assessing HIV strain variations in vaccine efficacy. , 2001, Statistics in medicine.

[38]  A. Ammann,et al.  Polyvalent pneumococcal-polysaccharide immunization of patients with sickle-cell anemia and patients with splenectomy. , 1977, The New England journal of medicine.

[39]  J. Henrichsen,et al.  Six newly recognized types of Streptococcus pneumoniae , 1995, Journal of clinical microbiology.

[40]  G. Maude,et al.  Prevention of pneumococcal infection in children with homozygous sickle cell disease. , 1984, British medical journal.

[41]  N. Sugaya,et al.  Efficacy of inactivated vaccine in preventing antigenically drifted influenza type A and well-matched type B. , 1994, JAMA.

[42]  D R Burton,et al.  Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. , 1994, Science.

[43]  A. Trkola,et al.  HIV type 1 coreceptors, neutralization serotypes, and vaccine development. , 1997, AIDS research and human retroviruses.

[44]  M H Gail,et al.  Applicability of sample size calculations based on a comparison of proportions for use with the logrank test. , 1985, Controlled clinical trials.

[45]  C. R. Mehta,et al.  StatXact : a statistical package for exact non-parametric inference, Cytel Software Corporation, Cambridge, MA, USA , 1990 .

[46]  Groen,et al.  Multivariate analysis of human immunodeficiency virus type 1 neutralization data , 1996, Journal of virology.

[47]  W. Szmuness,et al.  A controlled clinical trial of the efficacy of the hepatitis B vaccine (heptavax B): A final report , 1981, Hepatology.

[48]  M. L. Clements-Mann.  Lessons for AIDS vaccine development from non-AIDS vaccines. , 1998, AIDS research and human retroviruses.

[49]  B. Korber,et al.  A new classification for HIV-1 , 1998, Nature.

[50]  M. Hilleman,et al.  Protective efficacy of pneumococcal polysaccharide vaccines. , 1977, JAMA.

[51]  T. Jukes.  CHAPTER 24 – Evolution of Protein Molecules , 1969 .

[52]  J. Anderson.  Separate sample logistic discrimination , 1972 .

[53]  M. Champe,et al.  Neutralization of multiple laboratory and clinical isolates of human immunodeficiency virus type 1 (HIV-1) by antisera raised against gp120 from the MN isolate of HIV-1 , 1992, Journal of virology.

[54]  A. Agresti,et al.  Categorical Data Analysis , 1991, International Encyclopedia of Statistical Science.

[55]  J. Cuzick.  The Efficiency of the Proportions Test and the Logrank Test for Censored Survival Data , 1982 .

[56]  S. Hadler,et al.  The prevention of hepatitis B with vaccine. Report of the centers for disease control multi-center efficacy trial among homosexual men. , 1982, Annals of internal medicine.